Therapeutic potential targeting podocyte mitochondrial dysfunction in focal segmental glomerulosclerosis

<b><i>Background:</i></b> Podocytes are essential components of the glomerular filtration barrier and for proper function glomerulus. Podocyte injury under various stress conditions is primary pathogenesis key determinant focal segmental glomerulosclerosis (FSGS) with prominent clinical manifestations proteinuria or nephrotic syndrome. <b><i>Summary:</i></b> Under physiological conditions, a highly coordinated mitochondrial quality control system, including antioxidant defenses, dynamics (fusion, fission, mitophagy), biogenesis, guarantees sophisticated structure functions podocytes. However, FSGS pathological mitochondria encounter oxidative stress, disturbances, defective biogenesis. Moreover, mutations in DNA mitochondria-related genes also strongly associated FSGS. Based on these pieces evidence, bioactive agents that to relieve promote biogenesis have been proven effective preclinical models. Targeting network expected provide new therapeutic strategies treatment delay its progression end-stage renal disease. <b><i>Key Messages:</i></b> Mitochondrial dysfunction plays role podocyte progression. This review summarized recent advances study homeostatic imbalance discussed potential mitochondria-targeted therapeutics improving retarding